This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
by Zacks Equity Research
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
JNJNegative Net Change TAKNegative Net Change SYREPositive Net Change
biotechs medical pharmaceuticals
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
by Zacks Equity Research
Roche's Q1 beat masks currency drag as strong drug demand drives CER growth and offsets biosimilar hit to legacy portfolio.
RHHBYNegative Net Change NVOPositive Net Change LLYNegative Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
by Ahan Chakraborty
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
by Ahan Chakraborty
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
by Ahan Chakraborty
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALKS stock based on the movements in the options market lately.
ALKSNegative Net Change
biotechnology biotechs medical
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
by Zacks Equity Research
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
CPRXNegative Net Change INOPositive Net Change ADMAPositive Net Change INBXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 Earnings
by Ahan Chakraborty
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q1 results as investor focus broadens beyond GLP-1s.
AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
by Sundeep Ganoria
ABBV nears Q1 earnings with rising sales forecasts, but Humira erosion and weak ESP cloud outlook; can Skyrizi and Rinvoq momentum offset pressures?
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
by Kanishka Das
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
RGNXNegative Net Change MGTXNegative Net Change OCGNNegative Net Change
biotechs medical